GlassScriptPhysician profile
Jose A Vera
NPI 1669702270
$4,655.57
in general payments reported to CMS, 2019-2025
22 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,095 · 2022: $250 · 2023: $1,021 · 2024: $884 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,310.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $981.87 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $759.49 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $645.88 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $537.80 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $349.75 | 2025 | Cobenfy |
| Alkermes, INC. | $298.60 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $204.67 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $186.84 | 2021-2025 | Ingrezza |
| Corium, LLC | $136.79 | 2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $136.04 | 2021 | |
| Lundbeck LLC | $93.62 | 2021-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $81.67 | 2023 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $72.96 | 2024-2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.85 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $23.98 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $21.80 | 2024 | Dyanavel Xr |
| Bausch Health US, LLC | $21.70 | 2023 | Wellbutrin, Aplenzin |
| Ironshore Pharmaceuticals INC. | $19.49 | 2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $13.88 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $13.14 | 2021 | |
| Sage Therapeutics, LLC | $12.51 | 2021 | |
| Eisai INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Vera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.